168 related articles for article (PubMed ID: 19556322)
41. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.
Fehm T; Maimonis P; Weitz S; Teramoto Y; Katalinic A; Jäger W
Breast Cancer Res Treat; 1997 Mar; 43(1):87-95. PubMed ID: 9065602
[TBL] [Abstract][Full Text] [Related]
42. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
44. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
Bonnefoi H; Diebold-Berger S; Therasse P; Hamilton A; van de Vijver M; MacGrogan G; Shepherd L; Amaral N; Duval C; Drijkoningen R; Larsimont D; Piccart M
Ann Oncol; 2003 Mar; 14(3):406-13. PubMed ID: 12598346
[TBL] [Abstract][Full Text] [Related]
45. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
47. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
48. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
49. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
[TBL] [Abstract][Full Text] [Related]
50. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
[TBL] [Abstract][Full Text] [Related]
51. Expression of p16 and pRB in invasive breast cancer.
Shin E; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
[TBL] [Abstract][Full Text] [Related]
52. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
53. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
[TBL] [Abstract][Full Text] [Related]
54. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
55. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
56. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
[TBL] [Abstract][Full Text] [Related]
57. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
58. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
60. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.
Aleskandarany MA; Green AR; Rakha EA; Mohammed RA; Elsheikh SE; Powe DG; Paish EC; Macmillan RD; Chan S; Ahmed SI; Ellis IO
Int J Cancer; 2010 Apr; 126(7):1761-9. PubMed ID: 19711345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
